Leica Biosystems and Bio-Techne Expand Partnership to Enable Protease-Free Workflows for Automated Spatial Multiomics on the BOND RX Research Staining Instrument

Melbourne, Australia – April 2, 2025 – Leica Biosystems, a global leader in anatomic pathology solutions, and Advanced Cell Diagnostics (ACD), a Bio-Techne brand and a global leader in spatial biology, today announced an expansion of their longstanding partnership to offer innovative spatial multiomic solutions. This collaboration now includes automation of ACD’s new RNAscope™ Multiomic LS Assay and protease-free workflows on the BOND RX research staining instrument, further advancing the capabilities of spatial biology research.

The RNAscope™ Multiomic LS Assay enables simultaneous fluorescent detection of up to six RNA and/or protein biomarkers on the same slide, preserving RNA and protein integrity while maintaining tissue morphology. Additionally, ACD introduces a protease-free workflow for RNAscope™ 2.5 single-plex assays on the Leica BOND RX staining instrument, further advancing multiomic visualization from discovery research to translational applications.

"The automation of Bio-Techne's innovative RNAscope™ protease-free enabled assays on the Leica BOND RX platform marks a significant milestone in spatial multiomics research," said Dr. Matt McManus, President of Bio-Techne's Diagnostics & Spatial Biology Segment. "By enabling high-precision visualization of RNA and protein biomarkers on the same slide, we are empowering researchers with a streamlined, fully automated solution that preserves sample integrity and accelerates scientific discoveries in translational and clinical research."

The RNAscope™ in situ spatial assays have been widely adopted by top academic institutions, pharmaceutical companies, and service providers worldwide, contributing to over 12,000 peer-reviewed publications. This expansion builds on the strong partnership between Bio-Techne and Leica Biosystems, established in 2015, to deliver automated in situ hybridization (ISH) workflows that streamline spatial biology research.

“At Leica Biosystems, we are committed to empowering researchers with innovative solutions that accelerate spatial biology discovery,” said Karan Arora, Senior Vice President of Advanced Assays and Pharma Services at Leica Biosystems. “The integration of ACD’s RNAscope™ Multiomic LS Assay on the BOND RX reinforces our mission to provide cutting-edge tools that enhance precision and scalability in life science research.”

To learn more about Bio-Techne’s in situ spatial assays automated on the BOND RX research staining instrument, visit: Advanced Cell Diagnostics (ACD), a Bio-Techne brand

For Research Use Only. Not For Use In Diagnostic Procedures.

About Leica Biosystems

Leica Biosystems is a cancer diagnostics company and a global leader in anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of its corporate culture. Leica Biosystems is proud to be a Danaher Corporation subsidiary.

About Bio-Techne Corporation (NASDAQ: TECH)
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at Facebook, LinkedIn, Twitter or YouTube. 

Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416